Treatment of Fibromyalgia with Neurostimulation: a Randomized, Double-Blinded, Sham-Controlled Trial

Jeffrey Hargrove; R. Michael Gendreau; Donald Deering; Judith Gendreau

Treatment of Fibromyalgia with Neurostimulation: a Randomized, Double-Blinded, Sham-Controlled Trial

Jeffrey Hargrove, R. Michael Gendreau, Donald Deering, Judith Gendreau

Kettering University

Research output: Contribution to journal › Article › peer-review

Abstract

Background/Purpose: NeuroPoint is a medical device designed to provide noninvasive brain stimulation using a proprietary approach to deliver very low energy levels to deep brain structures. NeuroPoint provides a therapy referred to as “reduced impedance noninvasive cortical electrostimulation” (RINCE). An initial feasibility study of 77 patients diagnosed with fibromyalgia (FM) was conducted between 2006 and 2008. The current pilot study was designed to further evaluate the safety and efficacy of RINCE therapy in the treatment of FM.

Original language	American English
Journal	Arthritis Rheumatology
Volume	66
State	Published - Oct 1 2014

Keywords

Fibromyalgia
Neurology
Pain

Disciplines

Bioelectrical and Neuroengineering
Engineering

Access to Document

https://onlinelibrary.wiley.com/toc/23265205/2014/66/S10

Cite this

@article{0a9baa712c7b4bc989e38e627719b35a,

title = "Treatment of Fibromyalgia with Neurostimulation: a Randomized, Double-Blinded, Sham-Controlled Trial",

abstract = " Background/Purpose: NeuroPoint is a medical device designed to provide noninvasive brain stimulation using a proprietary approach to deliver very low energy levels to deep brain structures. NeuroPoint provides a therapy referred to as “reduced impedance noninvasive cortical electrostimulation” (RINCE). An initial feasibility study of 77 patients diagnosed with fibromyalgia (FM) was conducted between 2006 and 2008. The current pilot study was designed to further evaluate the safety and efficacy of RINCE therapy in the treatment of FM.",

keywords = "Fibromyalgia, Neurology, Pain",

author = "Jeffrey Hargrove and Gendreau, {R. Michael} and Donald Deering and Judith Gendreau",

year = "2014",

month = oct,

day = "1",

language = "American English",

volume = "66",

journal = "Arthritis Rheumatology",

}

TY - JOUR

T1 - Treatment of Fibromyalgia with Neurostimulation: a Randomized, Double-Blinded, Sham-Controlled Trial

AU - Hargrove, Jeffrey

AU - Gendreau, R. Michael

AU - Deering, Donald

AU - Gendreau, Judith

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background/Purpose: NeuroPoint is a medical device designed to provide noninvasive brain stimulation using a proprietary approach to deliver very low energy levels to deep brain structures. NeuroPoint provides a therapy referred to as “reduced impedance noninvasive cortical electrostimulation” (RINCE). An initial feasibility study of 77 patients diagnosed with fibromyalgia (FM) was conducted between 2006 and 2008. The current pilot study was designed to further evaluate the safety and efficacy of RINCE therapy in the treatment of FM.

AB - Background/Purpose: NeuroPoint is a medical device designed to provide noninvasive brain stimulation using a proprietary approach to deliver very low energy levels to deep brain structures. NeuroPoint provides a therapy referred to as “reduced impedance noninvasive cortical electrostimulation” (RINCE). An initial feasibility study of 77 patients diagnosed with fibromyalgia (FM) was conducted between 2006 and 2008. The current pilot study was designed to further evaluate the safety and efficacy of RINCE therapy in the treatment of FM.

KW - Fibromyalgia

KW - Neurology

KW - Pain

UR - https://digitalcommons.kettering.edu/mech_eng_facultypubs/44

UR - https://onlinelibrary.wiley.com/toc/23265205/2014/66/S10

M3 - Article

VL - 66

JO - Arthritis Rheumatology

JF - Arthritis Rheumatology

ER -

Treatment of Fibromyalgia with Neurostimulation: a Randomized, Double-Blinded, Sham-Controlled Trial

Abstract

Keywords

Disciplines

Access to Document

Other files and links

Cite this